Xeris Biopharma Holdings, Inc. (XERS) ownership: insiders 5% · institutions 58% · index and ETF funds 5% (13F 2026-03-31). Insider activity, 90 days: Routine (12 sales, 0 open-market buys). SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| BlackRock | 12945785.00 | $75.09M | 7.5% | 2026-03-31 |
| Vanguard | 11000660.00 | $63.80M | 6.4% | 2026-03-31 |
| D. E. Shaw | 7788811.00 | $45.18M | 4.5% | 2026-03-31 |
| State Street | 4658174.00 | $27.02M | 2.7% | 2026-03-31 |
| Geode Capital Management | 4290629.00 | $24.89M | 2.5% | 2026-03-31 |
| Qube Research & Technologies Ltd | 4114425.00 | $23.86M | 2.4% | 2026-03-31 |
| Rosalind Advisors, Inc. | 3231700.00 | $18.74M | 1.9% | 2026-03-31 |
| Nuveen (TIAA) | 2916598.00 | $16.92M | 1.7% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-08-12 | |
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-08-01 | |
| Sell | null | 2026-08-01 | |
| Sell | null | 2026-07-06 | |
| Sell | null | 2026-07-06 | |
| Sell | null | 2026-07-01 |
Back to XERS overview · XERS earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.